Lombard on verge of pivotal trial for Aorfix
This article was originally published in Clinica
Lombard Medical Technologies is on the verge of beginning US pivotal trials for its Aorfix stent graft for treating abdominal aortic aneurysms (AAAs), after it received conditional approval from the US FDA of its supplemental investigational device exemption (IDE) application.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.